Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?

Alyssa M Peckham Austin De La Cruz Robert L Dufresne

Published in: The mental health clinician (2018)

Buprenorphine/samidorphan has shown favorable results for efficacy and tolerability in premarketing studies evaluating its use as adjunctive therapy for treatment-resistant MDD. Its novel mechanism targeting the opioid pathway may serve as a promising antidepressant devoid of abuse potential.

Keyphrases

chronic pain
pain management
major depressive disorder
nuclear factor
depressive symptoms
open label
bipolar disorder
cancer therapy
sleep quality
case control
immune response
physical activity
study protocol